The Thai Food and Drug Administration (FDA) and China’s National Medical Products Administration (NMPA) have signed a Memorandum of Understanding (MOU) to bolster the regulatory oversight of health products. This partnership covers four key product categories: pharmaceuticals, herbal medicines, medical devices, and cosmetics. 

On November 14, 2024, representatives from the Thai FDA and the NMPA, led by Mr. LI Li, Commissioner of China’s National Medical Products Administration or NMPA, convened for the signing ceremony. The MOU aims to establish a cooperative framework grounded in equality and reciprocity, facilitating regulatory exchanges and collaboration between Thailand and China on health product oversight. 

Dr. Surachoke Tangwiwat, Secretary-General of the Thai FDA, highlighted NMPA's ongoing advancements in regulatory innovation and excellence. The NMPA has set benchmarks in regulatory science, consumer protection, and health product quality. It has also achieved WHO-level recognition as a national vaccine regulatory authority.  In today’s borderless health landscape, this collaboration signifies shared values and mutual efforts between Thailand and China to strengthen joint regulatory capacities. It also lays the groundwork for strategic partnerships, fostering economic ties, enhancing consumer protection, and promoting innovation. 

The Secretary-General of the FDA emphasized that the FDA and the NMPA have officially had the opportunity to collaborate. This partnership will progress with unity and shared goals. By studying and learning from each other's strengths, a future of health product regulation can be established to the highest standards, ensuring the improved well-being of Thai and Chinese citizens.

 **************************************************************
Published on November 15, 2024